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Abstract
Background:
Tyrosine kinase inhibitors (TKI) are the current
standard therapy for patients with chronic myeloid leukemia
(CML). Fluid retention and pleural effusions have been reported
in patients treated with TKIs, particularly with dasatinib. Although
TKIs have been shown to reverse pulmonary hypertension (PH)
in animal models, there have been some reports of development
of reversible PH with dasatinib. Methods: We conducted a
retrospective analysis on 401 patients diagnosed with CML in
chronic phase (CP) who were treated with TKIs (imatinib,
dasatinib, or nilotinib) as initial therapy for CML and had a
transthoracic echocardiogram (TTE) done at some point during
the course of therapy. PH was diagnosed if the patient had an
estimated right ventricular systolic pressure (RVSP) of 35 mm Hg
or greater. Secondary causes of PH (systolic or diastolic
dysfunction on TTE, chronic obstructive pulmonary diseases
[COPD], obstructive sleep apnea [OSA] and pulmonary
embolism) were investigated during chart review. Results:
Twenty (23%) out of 87 patients had evidence of PH by TTE;
median age 57 years, with 46% being males. Six pts (30%)
received nilotinib 400mg twice daily, 4 (20%) patients had
imatinib (400mg; n=1, 600mg; n=1 and 800mg daily; n=2), and 10
(50%) patients received dasatinib (dose varied 40-140mg daily).
Five (25%) patients had coronary artery disease, 9 (45%) had
systemic hypertension, 2 (10%) had COPD and 3 (15%) had
OSA. Thirteen pts had serial TTE to compare the progression of
PH including 6 (7%) who had a TTE prior to starting TKI. Among
these 13 pts with serial TTE, 7 had rising RVSP with one patient
having mild global hypokinesia, another with diastolic dysfunction
and another with OSA. Four of those 7 patients had normal
RVSP on their TTE prior to starting therapy. Six other pts had
improvement in the RVSP on serial TTE, 4 of them with systemic
hypertension. Two of those 6 patients had elevated RVSP on
their TTE prior to starting therapy; one pt had no change. Eleven
patients had pleural effusions (7 dasatinib, 3 imatinib, 1 nilotinib)
associated with PH. Conclusions: TKI therapy is occasionally
associated with development of PH, but RVSP may improve
spontaneously in some patients. A prospective study is needed to
further investigate the relationship between TKIs and the
development of PH.

Background
• Pulmonary hypertension (PH) is characterized by
elevated pulmonary artery pressure, right
ventricular hypertrophy and, eventually, right
ventricular failure.
• Unexplained PH has been described in some
myeloproliferative disorders, however evidence is
lacking in patients with CML 1.
• There have been some reports on the occurrence
of reversible PH after treatment with dasatinib2, 3.

Objectives
• To investigate the frequency and characteristics of
PH in patients with CML receiving therapy with
tyrosine kinase inhibitors (TKIs).

Patients and Methods
• Chart review of patients with CML treated with
TKIs at MDACC between 2000 and 2009.
• Included patients with CML in chronic phase
(CP) enrolled in several studies using imatinib
(800 mg orally daily), nilotinib (400 mg BID) or
dasatinib (100mg orally daily) as frontline
therapy who had at least one trans-thoracic
echocardiogram (TTE) done at baseline or
during the course of therapy.
• Patients with CML CP who had received prior
therapies were excluded.

Results
• Of 401 patients with CML treated with TKI as
initial therapy, 87 had at least one TTE done
• Among 28 patients with pre-therapy (baseline)
TTE, 8 (29%) patients had an elevated right
ventricular systolic pressure (RVSP) at
baseline.
• Elevated
RVSP
suggesting
pulmonary
hypertension during therapy occurred in 20
(23%) of 87 patients.
• Elevated RVSP was seen most commonly in
patients treated with dasatinib (occurring in 10
of 19 patients [53%]) [mean 36 mmHg, range
35-50 mmHg] and nilotinib (seen on 6 of 14
patients [43%]) [mean 36 mmHg, range 31-50
mmHg] (Table 2).
• LVEF remained normal in 18 (90%) of the 20
patients with elevated RVSP, suggesting that
PH could possibly be related to the use of TKIs.
• 70% of patients with elevated RVSP while on
therapy with dasatinib had evidence of
concomitant pleural effusions.
• Only 4 of 54 (8%) patients treated with imatinib
had evidence of elevated RVSP (2 had other
possible etiologies).

Results
• Of the patients that had elevated RVSP (suggesting
PH), 13 patients had serial TTE during therapy
(figure 1).

Figure 1. Algorithm of Patients with elevated RVSP who had serial TTE

• 7 patients experienced worsening PH (receiving
Dasatinib n=2, Imatinib n=2, Nilotinib n= 3)

6
Pre-TKI TTE available
(3 had elevated RVSP at
baseline)

• 4 had resolution (receiving imatinib n=2,
dasatinib n=3, nilotinib n=1) while on therapy.
The improvement in RVSP was seen after
switching from the TKI to another agent
(Dasatinib n=2, nilotinib n=1) or reducing the
dose of dasatinib by 50% (N=1).

2
RVSP improved
after therapy
(2/2 nilotinib)

• 2 of 3 patients with elevated RVSP at baseline
normalized after starting therapy with nilotinib.
• Pleural effusion was identified in 11 patients (55%)
with elevated RVSP (Table 3).
• Pleural effusion occurred most frequently among
patients on dasatinib (70%).

Table 1. Patient’s Characteristics
Median (range)
Age (y)

N° (%)

TKI

11 (55)

Median follow-up (months)

16 (2-54)

Median WBC (x109/L)

27.2 (2.7156.5)

Platelets (x109/L)

228 (70-599)

Hemoglobin (g/dl)

12.2 (6.2-14.1)

Splenomegaly

4
RVSP worsened
after therapy (one
had elevated RVSP
at baseline)
(1 dasatinib, 1
imatinib, 2 nilotinib)

Table 2. TTE evidence of PH by
therapy

56 (30-82)

Males

17 (51)

Imatinib

N
N
Elevated
TTE
RVSP on
Available
TTE (%)

54

4 (8)

2 (10)

Sokal score
High
Intermediate
Low

3 (15)
5 (25)
12 (60)

Medical History
Pleural effusion during TKI
Systemic Hypertension
Tobacco smoking
Coronary artery disease
Diastolic heart failure
Atrial Fibrillation
Obstructive sleep Apnea
COPD
Systolic heart failure

11 (55)
9 (45)
8 (40)
5 (25)
4 (20)
3 (15)
3 (15)
2 (10)
2 (10)

WBC= White blood cell, COPD= Chronic Obstructive Pulmonary Disease., y=
years

13
>1 TTE

Dasatinib 19

10 (53)

Nilotinib

6 (43)

14

N
Possible
secondary
cause of
elevated
RVSP
2 had
ischemic
CAD with
low EF that
worsened
after starting
TKI
2 had
COPD, 1
had OSA
2 had OSA
(with normal
RVSP prior
to starting
TKI)

TKI, tyrosine kinase inhibitor; TTT, transthoracic echocardiogram; RVSP,
right ventricle systolic pressure; CAD, coronary artery disease; EF ejection
fraction; COPD, chronic obstructive pulmonary disease.

• PH occurs in some patients with CML in
chronic phase at baseline while in others it
appears during therapy with TKI
7
No pre-TKI TTE
available

4
RVSP improved
while on therapy
(Dasatinib: 2
Stopped , 1 dose
reduced by 50%
Nilotinib: 1 stopped)

3
RVSP worsened or
stable while on
therapy
(1 dasatinib, 1
imatinib, 1 nilotinib)

Table 3. Incidence of pleural
effusion

TKI used

Imatinib

Conclusions

N
Concomitant
PE and
elevated
RVSP

N
of patients
with SOB

3 of 4 (75%)

1

Dasatinib

7 of 10 (70%)

4

Nilotinib

1 of 6 (17%)

0

TKI, tyrosine kinase inhibitor; RSVP, right ventricle systolic
pressure, PE= Pleural Effusion

• PH is seen less commonly in patients on
imatinib compared to dasatinib or nilotinib.
• Concomitant pleural effusion and PH
occurred more frequently in patients
receiving dasatinib.
• Unclear whether there is a causal
relationship between TKI and PH.
• A larger prospective study is needed to
further investigate the relationship between
TKIs and the development of PH.
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